mCRPC: Enzalutamide benefit is independent of concurrent corticosteroid use

Key clinical point: In patients with metastatic castration-resistant prostate cancer (mCRPC), enzalutamide improves outcomes independent of concurrent corticosteroid use (CCU).

Major finding: In patients with baseline CCU, enzalutamide vs placebo improved overall survival (OS; hazard ratio [HR], 0.70; P = .012), radiographic progression-free survival (rPFS; HR, 0.59; P < .001), and time to prostate-specific antigen progression (TTPP; HR, 0.36; P < .001). Enzalutamide improved OS (HR, 0.59; P < .001), rPFS (HR, 0.33; P < .001) and TTPP (HR, 0.22; P < .001) in patients with no CCU.

Study details: A post hoc analysis of phase 3, randomized AFFIRM trial of 1,199 patients with mCRPC who were randomly assigned to enzalutamide 160 mg/day or placebo.

Disclosures: This work was supported by Pfizer Inc. and Astellas Pharma, Inc. The authors received honoraria, advisory/consulting fees, nonfinancial support, and/or research funding outside this work. Some authors reported being employed, held patents, and/or were inventors or investigators.

Source: Zhao JL et al. Clin Cancer Res. 2021 Dec 29. doi: 10.1158/1078-0432.CCR-21-1090.

Key clinical point: In patients with metastatic castration-resistant prostate cancer (mCRPC), enzalutamide improves outcomes independent of concurrent corticosteroid use (CCU).

Major finding: In patients with baseline CCU, enzalutamide vs placebo improved overall survival (OS; hazard ratio [HR], 0.70; P = .012), radiographic progression-free survival (rPFS; HR, 0.59; P < .001), and time to prostate-specific antigen progression (TTPP; HR, 0.36; P < .001). Enzalutamide improved OS (HR, 0.59; P < .001), rPFS (HR, 0.33; P < .001) and TTPP (HR, 0.22; P < .001) in patients with no CCU.

Study details: A post hoc analysis of phase 3, randomized AFFIRM trial of 1,199 patients with mCRPC who were randomly assigned to enzalutamide 160 mg/day or placebo.

Disclosures: This work was supported by Pfizer Inc. and Astellas Pharma, Inc. The authors received honoraria, advisory/consulting fees, nonfinancial support, and/or research funding outside this work. Some authors reported being employed, held patents, and/or were inventors or investigators.

Source: Zhao JL et al. Clin Cancer Res. 2021 Dec 29. doi: 10.1158/1078-0432.CCR-21-1090.

Key clinical point: In patients with metastatic castration-resistant prostate cancer (mCRPC), enzalutamide improves outcomes independent of concurrent corticosteroid use (CCU).

Major finding: In patients with baseline CCU, enzalutamide vs placebo improved overall survival (OS; hazard ratio [HR], 0.70; P = .012), radiographic progression-free survival (rPFS; HR, 0.59; P < .001), and time to prostate-specific antigen progression (TTPP; HR, 0.36; P < .001). Enzalutamide improved OS (HR, 0.59; P < .001), rPFS (HR, 0.33; P < .001) and TTPP (HR, 0.22; P < .001) in patients with no CCU.

Study details: A post hoc analysis of phase 3, randomized AFFIRM trial of 1,199 patients with mCRPC who were randomly assigned to enzalutamide 160 mg/day or placebo.

Disclosures: This work was supported by Pfizer Inc. and Astellas Pharma, Inc. The authors received honoraria, advisory/consulting fees, nonfinancial support, and/or research funding outside this work. Some authors reported being employed, held patents, and/or were inventors or investigators.

Source: Zhao JL et al. Clin Cancer Res. 2021 Dec 29. doi: 10.1158/1078-0432.CCR-21-1090.